|
Idelalisib With Rituximab Boosts Survival in Relapsed CLL
Medscape In a phase 3 trial, known as Study 116, the investigational agent idelalisib (under development by Gilead), when added to rituximab (Rituxan), improved outcomes in patients with relapsed CLL. “Idelalisib is a targeted, highly selective, orally … Idelalisib plus rituximab extended survival in previously treated CLLHealio Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network Gilead’s Pipeline EncouragesYahoo News |
Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies … – Benzinga
|
Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies …
Benzinga Roche (OTC: RHHBY) and Prothena Corporation plc (Nasdaq: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal … Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co …MarketWatch Roche, Prothena ink potential $600 million deal for Parkinson’s diseaseSan Francisco Business Times (blog) RTT News –Seeking Alpha all 10 news articles » |
MDA Accuses Ethiopian MK of Provocation over Blood – Arutz Sheva
MDA Accuses Ethiopian MK of Provocation over BloodArutz ShevaKnesset Speaker MK Yuli Edelstein (Likud-Beytenu) expelled a Magen David Adom (MDA) team from the Knesset after it allegedly refused to take a blood donation from MK Pnina Tamano-Shata (Yesh …
Acute kidney injury worsens CV, renal outcomes in MI – Healio
Acute kidney injury worsens CV, renal outcomes in MIHealioPatients with MI who develop acute kidney injury are at increased risk for major adverse cardiac and renal events than those with kidney injury or MI alone, according to recent study findings. T…
Kidney Transplantation Global Clinical Trials Review, H2, 2013 – SBWire (press release)
|
Kidney Transplantation Global Clinical Trials Review, H2, 2013
SBWire (press release) Albany, NY — (SBWIRE) — 12/11/2013 — Clinical trial report, Kidney Transplantation Global Clinical Trials Review, H2, 2013″ provides data on the Kidney Transplantation clinical trial scenario. This report provides elemental information and data … |
Study identifies new way to predict prognosis for heart failure patients – Medical Xpress
Study identifies new way to predict prognosis for heart failure patientsMedical XpressJohns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better p…
RAA Inhibitors Tied to Longer Survival With Chronic Kidney Disease – Medscape
MedscapeRAA Inhibitors Tied to Longer Survival With Chronic Kidney DiseaseMedscapeNEW YORK (Reuters Health) Dec 10 – Patients with chronic kidney disease (CKD) who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor bloc…
Johns Hopkins researchers identify a new way to predict the prognosis for … – EurekAlert (press release)
Johns Hopkins researchers identify a new way to predict the prognosis for …EurekAlert (press release)Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which one…
CCS issues guidelines to improve early diagnosis and effective treatment of … – Medical Xpress
|
CCS issues guidelines to improve early diagnosis and effective treatment of …
Medical Xpress The Children’s Heart Failure Study Group of the Canadian Cardiovascular Society, in collaboration with the Canadian Pediatric Cardiology Association, has developed new guidelines to assist practitioners in primary care and emergency departments to … |
Dr. Reddy's Targets Roche's Rituxan in Europe: Corporate India – Businessweek
|
Dr. Reddy’s Targets Roche’s Rituxan in Europe: Corporate India
Businessweek Making a version of rituximab, the ingredient in cancer-treatment Rituxan, is where “the big opportunity is in the developed markets, clearly; that’s where the big sales are,” he said. Dr. Reddy’s joins larger rivals including Novartis AG and Pfizer … |